Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A. Pessino A, et al. Among authors: bennicelli e. Ann Oncol. 2008 Apr;19(4):711-6. doi: 10.1093/annonc/mdm516. Epub 2007 Dec 10. Ann Oncol. 2008. PMID: 18073221 Free article. Clinical Trial.
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C. Mammoliti S, et al. Among authors: bennicelli e. Ann Oncol. 2011 Apr;22(4):973-978. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20. Ann Oncol. 2011. PMID: 20855468 Free PMC article. Clinical Trial.
Chemotherapy: which drug and when?
Sobrero A, Bennicelli E. Sobrero A, et al. Among authors: bennicelli e. Ann Oncol. 2010 Oct;21 Suppl 7:vii130-3. doi: 10.1093/annonc/mdq293. Ann Oncol. 2010. PMID: 20943605 Free article. Review.
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. Gregorc V, et al. Among authors: bennicelli e. Br J Cancer. 2009 Jul 21;101(2):219-24. doi: 10.1038/sj.bjc.6605162. Epub 2009 Jun 30. Br J Cancer. 2009. PMID: 19568235 Free PMC article. Clinical Trial.
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Ramoni D, Coco S, Rossi G, Dellepiane C, Bennicelli E, Santamaria S, Zinoli L, Tagliafico AS, Tagliamento M, Barletta G, Liberale L, Tirandi A, Minetti S, Bertolotto M, Montecucco F, Genova C, Carbone F. Ramoni D, et al. Among authors: bennicelli e. Lung. 2024 Apr;202(2):197-210. doi: 10.1007/s00408-024-00675-5. Epub 2024 Mar 13. Lung. 2024. PMID: 38480620 Free PMC article.
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.
Cella E, Zullo L, Marconi S, Rossi G, Coco S, Dellepiane C, Alama A, Rozeboom L, Bennicelli E, Parisi F, Sacco G, Barletta G, Zinoli L, Tagliamento M, Pronzato P, Genova C. Cella E, et al. Among authors: bennicelli e. Expert Opin Biol Ther. 2022 Oct;22(10):1259-1273. doi: 10.1080/14712598.2022.2116273. Epub 2022 Aug 28. Expert Opin Biol Ther. 2022. PMID: 35994596 Review.
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center.
Vallome G, Cafaro I, Bottini A, Dellepiane C, Rossi G, Bennicelli E, Parisi F, Zullo L, Tagliamento M, Ballestrero A, Barisione E, Piroddi IMG, Montecucco F, Carbone F, Pronzato P, Lambertini M, Spagnolo F, Barletta G, Barcellini L, Ferrante M, Nardin S, Coco S, Marconi S, Zinoli L, Moscatelli P, Arboscello E, Del Mastro L, Bellodi A, Genova C. Vallome G, et al. Among authors: bennicelli e. Heliyon. 2023 Oct 19;9(11):e21177. doi: 10.1016/j.heliyon.2023.e21177. eCollection 2023 Nov. Heliyon. 2023. PMID: 37928020 Free PMC article.
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, Malapelle U, Genova C. Rebuzzi SE, et al. Among authors: bennicelli e. Int J Mol Sci. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625. Int J Mol Sci. 2021. PMID: 33807876 Free PMC article. Review.
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients.
Marconi S, Croce M, Chiorino G, Rossi G, Guana F, Profumo A, Ostano P, Alama A, Longo L, De Luca G, Dono M, Dal Bello MG, Ponassi M, Rosano C, Romano P, Cavalieri Z, Grassi M, Tagliamento M, Zullo L, Venturi C, Dellepiane C, Mastracci L, Bennicelli E, Pronzato P, Genova C, Coco S. Marconi S, et al. Among authors: bennicelli e. Cancers (Basel). 2022 Jul 14;14(14):3412. doi: 10.3390/cancers14143412. Cancers (Basel). 2022. PMID: 35884472 Free PMC article.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
15 results